Articles tagged as 'ISoP'

9 results

ISoP annual meeting looks to a new era of pharmacovigilance
ISoP’s 2022 annual meeting was themed “A New Era of Pharmacovigilance: Challenges and Opportunities”. Independent consultant Mary Stapleton shares her observations of the event.


ISoP European Chapter offers new opportunities for connection among members
As well as promoting PV research and training in Europe, the chapter aims to foster communication and collaboration between European institutions working in drug safety.


Pharmacovigilance, where science meets practice
The theme of this year’s ISoP mid-year symposium encouraged members to reflect on how PV scientists may work better with clinicians to ensure medicine safety for their patients.


Making fewer medication errors – Education and training remain key
Medication errors significantly contribute to the global number of ADRs per year. How may we best prepare the pharmacovigilance community to tackle the problem?


Pharmacogenomics group aims to refine patient safety options
Better understanding of genetic variation – between individuals and subpopulations – can inform more refined choices of drugs and doses. A new ISoP group is set to drive progress.


What’s trending in pharmacovigilance? New podcast episode
In this festive edition of Drug Safety Matters, we wrap up the year that was and look ahead to the year that will be – with a little help from one of our friends.


A new chapter opens in ISoP leadership
It was themed as “new opportunities for new generations”, and the 19th Annual Meeting of ISoP lived up to that billing with the announcement of its leadership election results.


ISoP Africa gets a fresh start with its first chapter meeting in Uganda
The meeting brought together nearly 300 experts to discuss advancing pharmacovigilance practice and local data-driven decision-making on the continent.


Guarding nature: The role of ecopharmacovigilance in preventing pharmaceutical pollution
EcoPV aims to monitor and manage the environmental impact of pharmaceuticals. How may we best support this effort?